AF
ARQT icon

Amalgamated Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Amalgamated Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$67K Buy
+3,459
New +$58.5K ﹤0.01% 2282

Other funds holding ARQT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Amalgamated Financial's ARQT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Arcutis Biotherapeutics (ARQT) in Q1 2022: 3,459 shares worth $67K. The stake represents ﹤0.01% of the portfolio and ranks #2282 among its holdings.

106 funds tracked by Wall St. Rank hold ARQT as of Q1 2022.

  • Amalgamated Financial held 3,459 shares of Arcutis Biotherapeutics worth $67K as of Q1 2022.
  • Arcutis Biotherapeutics was a new Amalgamated Financial position in Q1 2022.
  • Arcutis Biotherapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2282 holding.
  • 106 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.